For the latest COVID-19 (Coronavirus) information: CCTG public updates | CCTG member information

IC8 celebrates some early milestones

Wednesday, November 18, 2020

Great news to share from the CCTG IC8 trial team! The study already has 6 sites currently participating with 29 patients accrued. Congrats to all of the trial teams at:

  • Juravinski Cancer Centre at Hamilton Health Sciences - Contact: Rosalyn Anne Juergens      
  • Ottawa Hospital Research Institute - Contact: Rebecca Ann Auer  
  • Odette Cancer Centre - Contact: Martin Smoragiewicz
  • University Health Network - Contact: Grainne O'Kane   
  • CHUM-Centre Hospitalier de l'Universite de Montreal - Contact: David Roberge
  • The Research Institute of the McGill University - Contact: George Zogopoulos

About IC8

CCTG IC8: Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure (COV-IMMUNO). IMM-101 is a preparation of safe, heat-killed bacteria that broadly stimulates the innate, or “first-response,” arm of the immune system. Researchers hope that boosting cancer patients’ immune systems with IMM-101 will protect them from developing severe COVID-19 and other dangerous lung infections.

Researchers from The Ottawa Hospital came up with the idea for the trial and worked with CCTG to design and run it in centres across the country. Funding and in-kind support, is being provided by the Canadian Cancer Society, BioCanRx, the Ontario Institute for Cancer Research, The Ottawa Hospital Foundation, The Ottawa Hospital Academic Medical Organization, ATGen Canada/NKMax, and Immodulon Therapeutics, the manufacturer of IMM-101.

For more information about the trial please visit the IC8 CCTG trial page